Recent developments include corporate governance updates and strategic consulting agreements supporting the company's transition to laser-based computing technology.

• Q/C Technologies appointed Chelsea Voss, an AI and machine learning expert from OpenAI, as a director in January 2026, enhancing board expertise in technology [S1].
• The company entered into consulting agreements with industry experts including Ocean Avenue Holdings LLC and James Altucher to support strategic planning, fundraising, and business development [S1].
• Q/C Technologies announced new board and shareholder votes related to corporate governance matters in April 2026 [N1].
• News coverage includes announcements about TNF Pharmaceuticals and Renova Health's trial to explore isomyosamine, which are separate entities but appear in the company's news feed [N2].

The company’s pivot to laser-based computing for blockchain and AI infrastructure leverages cutting-edge photonic technology licensed exclusively from LightSolver Ltd., potentially enabling energy-efficient and high-performance computing solutions. If the qc-LPU100 and future LPUs achieve targeted performance and scalability, Q/C Technologies could establish a niche in the emerging decentralized computing and cryptocurrency infrastructure markets. The company’s strong patent portfolio and exclusive licensing agreements provide a foundation for competitive differentiation. Recent additions to the board with AI expertise and strategic consulting agreements may enhance execution capabilities.

The qc-LPU100 prototypes remain in early development without completed performance validation or regulatory certifications, introducing significant technical and commercialization risks. The company’s shift from pharmaceuticals to technology hardware markets involves operating in unfamiliar sectors with uncertain execution. The reliance on a single licensing partner, LightSolver Ltd., exposes the company to risks if the license is interrupted or intellectual property disputes arise. Financially, the company has reported substantial net losses and faces obligations related to Series H Preferred Stock dividends and restrictive covenants that may constrain financing options. Regulatory and cybersecurity risks in blockchain and cryptocurrency markets may further impact adoption and operations.

Q/C Technologies' moat is primarily based on its exclusive global licensing agreement with LightSolver Ltd. for photonic laser processing unit technology, which is central to its product development. The company holds a portfolio of issued and pending patents in multiple jurisdictions, providing some intellectual property protection. However, the technology is in early development stages, and the company faces risks related to patent challenges, technology integration, and the ability to commercialize the hardware at scale. The specialized nature of photonic computing and the exclusive license may provide a competitive edge if successfully developed and adopted, but the moat is contingent on successful execution and protection of intellectual property.

• Technology Development Risk: The qc-LPU100 and future laser processing units are in early-stage development and have not completed performance validation or regulatory certifications, which may delay or prevent commercialization.
• Intellectual Property Risk: Although the company holds multiple patents and an exclusive license with LightSolver Ltd., patents may be challenged or circumvented, and loss or limitation of the license could materially impair operations.
• Financial and Liquidity Risk: The company reported a net loss of $11.6 million for fiscal 2025 and has Series H Preferred Stock with dividend and redemption obligations that may require substantial cash outlays, potentially limiting financial flexibility.
• Regulatory and Market Risk: The company operates in highly regulated blockchain and cryptocurrency sectors with evolving compliance requirements, export controls, and cybersecurity risks that could affect market adoption and operational viability.
• Execution Risk: The strategic shift from pharmaceuticals to technology hardware markets involves new operational challenges and uncertainties in market acceptance, manufacturing scale-up, and competitive dynamics.

• Q/C Technologies, Inc. is a Delaware corporation headquartered in New York, NY.
• The company trades on The Nasdaq Capital Market under the ticker QCLS.
• As of April 27, 2026, the company had 7,853,429 shares of common stock outstanding.
• The company historically focused on pharmaceutical research and development, including Isomyosamine and Supera-CBD product candidates.
• Beginning in September 2025, Q/C Technologies shifted its business strategy to laser-based computing for blockchain, decentralized physical infrastructure networks (DePin Token), and high-performance computing.
• The company is developing the qc-LPU100, a laser processing unit prototype intended for energy-efficient blockchain and cryptocurrency infrastructure.
• The qc-LPU100 prototypes remain in early-stage development and have not completed performance validation or regulatory certifications.
• Q/C Technologies holds an exclusive global licensing agreement with LightSolver Ltd. for the deployment of LightSolver's LPU technology and photonic methodologies essential for the qc-LPU100.
• The company depends on LightSolver for intellectual property, know-how, improvements, and ongoing collaboration.
• Q/C Technologies has 19 issued U.S. patents, 70 foreign patents, and 4 foreign patent applications pending in jurisdictions including Canada, China, Israel, and Japan, with expected expirations between 2036 and 2041.
• The company reported a net loss of $11,627,122 for the fiscal year ended December 31, 2025, with basic and diluted EPS of -8.66 USD per share.
• As of December 31, 2025, Q/C Technologies had cash and cash equivalents of $986,996 and short-term investments of $14,801,267, totaling current assets of $16,580,558 against current liabilities of $5,532,042, resulting in a current ratio of 3.0 and a cash ratio of 2.85.
• The company has Series H Preferred Stock outstanding, which carries a 7% annual dividend compounded quarterly, payable in arrears starting October 1, 2025, and accrues at 15% during Triggering Events, potentially requiring substantial cash outlays.
• The Series H Preferred Stock and associated warrants contain anti-dilution provisions and restrictive covenants that may limit the company's financing flexibility and affect financial condition.
• Q/C Technologies' shift to blockchain and cryptocurrency infrastructure exposes it to regulatory risks including export controls, hardware certification requirements, and evolving cryptocurrency regulations across multiple jurisdictions.
• The company faces cybersecurity, data integrity, and operational risks related to DePin Token networks and blockchain applications.
• Recent board and management changes include the appointment of Chelsea Voss as a director in January 2026, who has AI and machine learning expertise.
• The company has entered into consulting agreements with industry experts to support strategic planning and business development.
• Recent news includes announcements related to TNF Pharmaceuticals and Renova Health, which are separate entities but appear in the news feed associated with the company [N1][N2].